1 Asamura H, Goya T, Koshiishi Y et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J. Thorac. Oncol. 2008; 3; 46–52.
2 Kelsey CR, Higgins KA, Peterson BL et al. Local recurrence after surgery for non-small cell lung cancer: a recursive parti-tioning analysis of multi-institutional data. J. Thorac. Cardiovasc.Surg. 2013; 146; 768–773
3 Zhang S, Zhai X, Wang G, et al. High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival. Int J Clin Exp Pathol. 2015 1;8(1):541-50.
4 Fan G, Zhang K, Ding J, et al. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2017, 16;8(20):33922-33932.
5 Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263:526-9.
6 Pemberton PA, Tripton AR, Pavloff MC. Maspin is an intracellular serpine that partitions into secretary vesicles and in present at the cell surface. J Histochem Cytochem 1997; 45:1697-706.
7 Umekita Y, Ohi Y, Sagaya Y, et al. Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer. 2002; 100:452-5.
8 Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res. 2002; 8:2924-32.
9 Maass N, Hojo T, Ueding M, et al. Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res. 2001; 7:812-7.
10 Takanami I, Abiko T, Koizumi S, et al. Expression of Maspin in Non–Small-Cell Lung Cancer: Correlation with Clinical Features. Clin Lung Cancer. 2008 Nov;9(6):361-6.
11 Katakura H, Takenaka K, Nakagawa M, et al. Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer. 2006 Mar;51(3):323-8.
12 Wu S, Yu L, Cheng Z, et al. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):346-352.
13 Takagi Y, Matsuoka Y, Shiomi T, et al. Cytoplasmic maspin expression is a predictor of poor prognosis in patients with lung adenocarcinoma measuring <3 cm. Histopathology. 2015 Apr;66(5):732-9.
14 Matsuoka Y, Takagi Y, Nosaka K, et al. Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung. Histopathology. 2016 Jul;69(1):114-20.
15 Lu M, Li J, Huang Z, et al. Aberrant Maspin mRNA Expression is Associated with Clinical Outcome in Patients with Pulmonary Adenocarcinoma. Med Sci Monit. 2016 Jan 13;22:134-9.
16 Vansteenkiste JF, Cho BC, Vanakesa T, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Jun;17(6):822-835.
17 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment
of the quality of nonrandomized studies in meta-analyses. Eurjepidemiol.2010; 25:603-605.
18 Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16.
19 Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997 Nov 1;127(9):820-6.
20 Hirai K, Koizumi K, Haraguchi S, et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann Thorac Surg. 2005 Jan;79(1):248-53.
21 Woenckhaus M, Bubendorf L, Dalquen P, et al. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J Clin Pathol. 2007 May;60(5):483-6.
22 Nakagawa M, Katakura H, Adachi M, et al. Maspin expression and its clinical significance in non-small cell lung cancer. Ann Surg Oncol. 2006 Nov;13(11):1517-23.
23 Wang X, Wang Y, Li S, et al. Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer. Thorac Cancer. 2014 Sep;5(5):383-90.
24 Yaman B, Nart D, Ekren PK, et al. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis. Turk Patoloji Derg. 2015;31(3):163-74.
25 Ohno T, Kubouchi Y, Wakahara M, et al. Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma. Anticancer Res. 2018 May;38(5):3001-3007.
26 Zhang M, Volpert O, Shi YH, et al. Maspin is an angiogenesis inhibitor. Nat Med
2000; 6:196-9.
27 Friedrich MG, Toma MI, Petri S, et al. Expression of maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur Urol 2004; 45:737-43.
28 Zou Z, Gao C, Nagaich AK, et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem. 2000,275:6051–4.
29 Goulet B, Kennette W, Ablack A et al. Nuclear localization of maspin is essential for its inhibition of tumour growth and metastasis. Lab. Invest. 2011; 91; 1181–1187.
30 Wu XC, Zheng YF, Tang M, et al. Association Between Smoking and p53 Mutation in Oesophageal Squamous Cell Carcinoma: A Meta-analysis. Clin Oncol (R Coll Radiol). 2015 Jun;27(6):337-44.